Clinical trials
Zika Virus Infection trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
77 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2015 | 1 |
| 2016 | 18 |
| 2017 | 17 |
| 2018 | 11 |
| 2019 | 6 |
| 2020 | 5 |
| 2021 | 6 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 58 |
| Unknown status | 7 |
| Withdrawn | 3 |
| Terminated | 3 |
| Enrolling by invitation | 2 |
| Recruiting | 2 |
| Suspended | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 12 |
| Institut Pasteur | 3 |
| ModernaTX, Inc. | 3 |
| University of Heidelberg Medical Center | 3 |
| GeneOne Life Science, Inc. | 2 |
| Oswaldo Cruz Foundation | 2 |
| RTI International | 2 |
| Themis Bioscience GmbH | 2 |
| Universidade Federal de Pernambuco | 2 |
| University Hospital Center of Martinique | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Zika Virus Infection | 77 |
| Chikungunya Fever | 27 |
| Dengue | 25 |
| Arbovirus Infections | 6 |
| Microcephaly | 6 |
| Malaria | 5 |
| Vector Borne Diseases | 4 |
| Leishmaniasis | 3 |
| Leptospirosis | 3 |
| Virus Diseases | 3 |
Trials
Showing 26 to 50 of 77. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.